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Methods: Patients with NSCLC who had received one prior che-
motherapy regimen were treated with celecoxib, 400mg twice daily, 
orally, and erlotinib, 150mg daily, orally, until disease progression. The 
planned accrual was 40 patients. Tissue was collected for EGFR analy-
sis and COX-2 staining by immunohistochemistry (IHC). 
Results: Twenty-six patients with stage IIIB/IV NSCLC were enrolled. 
Patient characteristics: male 65%; median age 66; ECOG performance 
status 0/1- 96%. Tissue was available for FISH and EGFR muta-
tion analysis for 18 patients and for COX-2 IHC for 21 patients. Two 
patients had a partial response (PR) and 8 patients had stable disease 
(SD). The median progression free survival (PFS) and overall survival 
(OS) were 1.9 and 10.2 months, respectively. Fifty percent of tested pa-
tients had chromosome 7 polysomy without a correlation with response 
or PFS. Eleven patients (52% of tested) had tumors with increased 
COX-2 expression which was strongly associated with prolonged PFS, 
p=.008. Two patients had an EGFR mutation present, one had a PR 
(exon 19) and one had progressive disease (exon 21). Four patients 
either on anticoagulation or with a history of peptic ulcer disease had 
Grade 3/4 upper gastrointestinal bleeding, prompting study closure. 
Three of these 4 patients had endoscopy and were found to have peptic 
ulcers. 
Conclusions: In this trial, the combination of erlotinib and celecoxib 
did not result in improved efﬁcacy compared with historical controls 
though it did suggest improved PFS in patients with increased expres-
sion of COX-2. However, the high incidence of gastrointestinal bleed-
ing in this group of patients suggests that the combination of COX-2 
inhibitors and EGFR-TKI should not be given to patients with a previ-
ous history of peptic ulcer disease or to patients requiring therapeutic 
anticoagulation. 
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Background: Prognostic factors associated with better outcomes 
(EGFR mutations (mut), high EGFR gene copy number, never smok-
ing) can be used to select pts for EGFR tyrosine kinase inhibitor (TKI) 
combination trials, but would exclude most NSCLC pts. Excluding 
pts with the worst likely outcomes may identify more pts who could 
beneﬁt from combination of a TKI with other agents. Our objective was 
to identify clinical and molecular characteristics associated with RPD 
(≤70 days) and shorter progression-free survival (PFS) in previously 
treated NSCLC pts receiving G.
Methods: Consecutive Expanded Access Trial pts with >1 week 
G were included for analysis. Tissue from 87 pts was evaluated for 
EGFR, pAKT, and PTEN protein expression by immunohistochemistry 
(IHC); 81 tumors were evaluated for gene copy number by ﬂuorescence 
in situ hybridization (FISH); 58 tumors were analyzed for mut and sum 
of CA dinucliotide repeats (∑CArepeats) by SSCP, PCR, and sequenc-
ing. EGFR and centromere 7 (CEN7) probes were utilized to examine 
EGFR/cell and CEN7/cell. Pts were classifed as FISH+ with high poly-
somy (≥4 copies of the EGFR gene in ≥40% of cells) or ampliﬁcation 
(EGFR gene/CEN7 ≥2, or ≥15 copies of EGFR genes per cell in ≥10% 
of cells), or FISH- (≤4 copies of the gene in >40% of cells).
Results: There were 150 pts; 77 female, median (md) age 67. Md fol-
low-up was 5.8 months (mo). Objective response was 8% (2CR, 10PR, 
56SD, 82RPD). Md Kaplan-Meier PFS and survival were 2.0 and 5.8 
mo, respectively. Table displays univariate results. Non-adenocarci-
noma histology (N-A-H), smoking, ≤12 mo from diagnosis to G (dx-
G≤12mo), lack of mut, and ∑CArepeats<34 were associated with RPD. 
Smoking, Mut-PTEN-, EGFR-PTEN-, and EGFR-pAKT- tumors were 
associated with shorter PFS. Separate clinical and molecular multivari-
ate models were developed. In logistic regressions, N-A-H, p=0.004, 
dx-G≤12mo, p=0.0009, lack of mut (p=0.0298), and ∑CArepeats<34 
(p=0.0622) were associated with RPD. In Cox regressions, N-A-H 
(p=0.0256), dx-G≤12mo (p=0.0166), and lack of mut (p=0.0298) were 
associated with shorter PFS. EGFR FISH variables, alone or combined 
with EGFR IHC, were not signiﬁcantly associated with RPD or PFS.
Conclusion: N-A-H, dx-G≤12mo, and lack of mut were associated 
with RPD and shorter PFS in univariate and multivariate analyses. 
∑CArepeats<34 and certain non-FISH double-negative molecular 
combinations were also related to worse outcome. These clinical and 
molecular characteristics may warrant further study as exclusion crite-
ria for TKI combination clinical trials.
Summary of Univariate Analyses
Variable n Pts (%)
n Pts with 
Rapid PD (%)
Chi-sq p Md PFS (mo) Log-rank p
Other histology 65 (43) 44 (68)
0.0051
1.9
0.0383
Adenocarcinoma 85 (57) 38 (45) 2.9
Smoker 130 (87) 75 (58)
0.0577
2.0
0.0013
Never smoked 20 (13) 7 (35) 8.7
≤12 mo from dx to G 88 (59) 58 (66)
0.0010
1.9
0.0233
>12 mo from dx to G 62 (41) 24 (39) 3.4
Mutation absent 41 (71) 18 (44)
0.0050
3.3
0.0010
Mutation present 17 (29) 1 ( 6) 13.6
Mutation- pAKT- 18 (32) 5 (28)
0.5455
4.0
0.4699
Any positive 39 (68) 14 (36) 3.9
Mutation- PTEN- 16 (30) 5 (31)
0.8331
3.8
0.0489
Any positive 38 (70) 13 (34) 4.3
∑CA repeats<34 30 (52) 14 (47)
0.0195
3.3
0.1505
∑CA repeats ≥34 28 (48) 5 (18) 4.8
EGFR IHC absent 40 (46) 19 (48)
0.3869
2.4
0.0680
EGFR IHC present 47 (54) 18 (38) 4.2
EGFR-PTEN- 16 (21) 6 (38)
0.8180
2.9
0.0290
Any positive 59 (79) 24 (41) 4.0
EGFR-pAKT- 18 (24) 9 (50)
0.3205
2.4
0.0607
Any positive 57 (76) 21 (37) 3.7
CEN7 polysomy <3.6/cell 63 (78) 29 (46)
0.0698
2.9
0.3461
CEN7 polysomy ≥3.6/cell 18 (22) 4 (22) 4.2
EGFR-CEN7- 31 (38) 15 (48)
0.2701
2.4
0.1180
Any positive 50 (62) 18 (36) 4.0
FISH- 45 (56) 20 (44)
0.4482
2.6
0.9607
FISH+ 36 (44) 13 (36) 3.9
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EGFR-FISH- 25 (31) 13 (52)
0.1682
2.3
0.1412
Any positive 56 (69) 20 (36) 4.0
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of erlotinib versus best supportive care after cisplatin based 
chemotherapy in advanced non-small-cell lung cancer (NSCLC)
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Background: NCIC CTG BR.21 is a landmark trial, establishing the 
epidermal growth factor receptor inhibitor erlotinib, as a second or 
third line treatment option for advanced NSCLC after failure of cispla-
tin based chemotherapy. Overall survival and quality of life outcomes 
were superior in the erlotinib arm compared to best supportive care, 
with an overall survival of 6.7 vs. 4.7 months (p<0.001). In view of this 
clinical beneﬁt, the cost effectiveness of erlotinib was investigated. 
Methods: Direct medical resource utilization data were collected 
from the BR.21 trial database. The analysis was performed based on 
Canadian Public Healthcare System perspective, using costs (CAD$ 
2006) from provincial sources. Direct medical costs include: drug, hos-
pitalizations; toxicity, procedures, transfusions and radiation therapy. 
Non-medical and indirect costs were not included. Average costs per 
treatment arm are calculated. 
Results: Utilization data were collected on 731 patients (100%), of 
which 488 patients were assigned to the erlotinib arm. Preliminary 
results show, an overall mean cost of erlotinib alone, per patient, is 
$10,584 and $11,642 with additional mark up fees. 
Conclusion: The predominant cost in the erlotinib arm is related to 
drug cost, but this may be within an acceptable level of health care 
expenditure. Cost effectiveness and costing in patient subgroups will be 
presented. 
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Background: ADC-BACs are distinguished from other ADCs by 
epidemiological, clinical and CT scan presentations as well as mo-
lecular biology, leading to some responses to EGF-TKI. We therefore 
conducted a prospective, multicentric, phase II trial to evaluate geﬁtinib 
(250 mg/d) as ﬁrst-line treatment in non-resectable ADC-BAC. 
Methods: Inclusion criteria were previously untreated, non-resectable 
cyto/pathologically proven ADC-BAC. Primary objective was disease 
control rate (DCR) at 3 months. Secondary exploratory objectives were 
progression free survival (PFS), overall survival (OS), and identiﬁca-
tion of factors associated with PFS and OS using multivariate cox 
model analyses. 
Results: From 04/04 to 06/05, 88/90 enrolled patients were eligible. All 
were caucasians with stage IV disease, PS <2 in 81.8%, age >70 yrs in 
36.4%, females in 54.4% and non-smokers in 43.2%. DC was achieved 
in 25/85 evaluable patients (DCR=29.3%, CI=[20-39]). Median PFS 
was 2.9 months (CI=[2.4-3.2]) and median survival 13.3 months 
(CI=[10.1-21.8]), with a 1-year survival of 55.7% (CI=[44.4-65.5]). DC 
was independently associated with age >70 yrs (OR=4.9, p=.047); nev-
er-smoking (OR=8.1, p=.015); Respiratory Symptoms Scale (RSS) <9 
(OR=18.7, p=.002); non-mucinous BAC (OR=15.1, p=.006) and rash 
(OR=2.1, p=.02). When DC at 3 months was not included as factor in 
the cox model, reduced risk of progression was independently associ-
ated with RSS <9 (HR=0.512, p=.03); non-mucinous BAC (HR=0.316, 
p=.01) and presence of rash (HR=0.440, p=.004). However, when DC 
was included in the model, reduced risk of progression was strongly 
associated with DCR (HR=0.025, p<.0001) with independent effect 
of non-mucinous BAC histology (HR=0.380, p=.04). When DC was 
not included as factor in the cox model, decreased risk for death was 
independently associated with initial stage I-IIIa (HR=0.213, p=.01); 
absence of bronchorrhea and oxygen support (HR=0.056, p=.01 and 
HR=0.349, p=.007); RSS <9 (HR=0.363, p=.003); and presence of rash 
(HR=0.338, p=.0007). However, DC at 3 months did not affect the risk 
for OS when included in the Cox model. 
Conclusions: Geﬁtinib seems active as ﬁrst-line treatment of non-
resectable ADC-BAC especially, in older patients, never-smokers, 
patients with fewer pulmonary symptoms and with non-mucinous BAC 
subtype. While DC by geﬁtinib at 3 months strongly predicted PFS, 
it did not independently inﬂuenced survival in the IFCT0401 popula-
tion. This suggested that ADC-BAC has been controlled by second-line 
chemotherapy given after progression under geﬁtinib in some patients 
of the IFCT0401 cohort. 
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Background: Epidermal Growth Factor - Tyrosine Kinase Inhibitors 
(EGFR-TKIs) and especially erlotinib, are authorized in Europe for 
the treatment of metastatic non-small cell lung cancer (NSCLC) after 
failure of, at least one, prior chemotherapy. Although, it has been sug-
gested that biological markers (EGFR over-expression, EGFR gene 
polysomy/ampliﬁcation and EGFR and K-ras mutations) are predictive 
of efﬁcacy of EGFR-TKIs, they are not used in clinical practice. In 
order to help implementation of these biomarkers in France, the French 
